Decades after state lawmakers created criminal charges penalizing people living with HIV in the name of public health, a bill ...
Investor's Business Daily on MSN
Gilead leads the battle vs. HIV but rivals are on the move
Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?
ACOG released updated clinical guidance on the screening and prevention of HIV, recommending several strategies and processes ...
More than 130 people, mostly children, tested HIV-positive in an outbreak linked to a government hospital in Karachi.
As people with HIV live longer, diabetes is becoming an increasingly important contributor to morbidity and mortality, ...
Some HIV prevention grants have been reduced under Trump, and some Atlanta advocates say they have already seen delays in funds arriving.
Millions of HIV/AIDS patients, many of them in Africa, face an uncertain future as a financial cliff-edge for US-funded ...
A new twice-yearly HIV prevention injection could transform South Africa's fight against the epidemic — but U.S. aid cuts and limited doses threaten to slow its impact.
Among treatment-naive adults living with HIV, CD4 to CD8 ratios do not differ significantly between those on dolutegravir ...
Gilead's expansion beyond HIV therapies will surprise many investors.
People taking antiretroviral therapy (ART) for HIV can achieve very low quantities of the virus in their blood, which standard blood tests cannot detect. Doctors describe these individuals as having ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results